Learning to play golf for elderly people with subjective memory complaints: feasibility of a single-blinded randomized pilot trial.
Alzheimer’s Disease
Cognitive Performance
Golf
Kynurenine pathway
Subjective memory complaints
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
17 May 2021
17 May 2021
Historique:
received:
26
11
2020
accepted:
24
03
2021
entrez:
18
5
2021
pubmed:
19
5
2021
medline:
24
6
2021
Statut:
epublish
Résumé
Subjective Memory Complaints (SMC) in elderly people due to preclinical Alzheimer's Disease may be associated with dysregulation of the Kynurenine Pathway (KP), with an increase in neurotoxic metabolites that affect cognition. Golf is a challenging sport with high demands on motor, sensory, and cognitive abilities, which might bear the potential to attenuate the pathological changes of preclinical AD. This trial investigated the feasibility of learning to play golf for elderly with cognitive problems and its effects on cognitive functions and the KP. In a 22-week single-blinded randomized controlled trial, elderly people with SMC were allocated to the golf (n = 25, 180 min training/week) or control group (n = 21). Primary outcomes were feasibility (golf exam, adherence, adverse events) and general cognitive function (Alzheimer's Disease Assessment Scale). Secondary outcomes include specific cognitive functions (Response Inhibition, Corsi Block Tapping Test, Trail Making Test), KP metabolites and physical performance (6-Minute-Walk-Test). Baseline-adjusted Analysis-of-Covariance was conducted for each outcome. 42 participants were analyzed. All participants that underwent the golf exam after the intervention passed it (20/23). Attendance rate of the golf intervention was 75 %. No adverse events or drop-outs related to the intervention occurred. A significant time*group interaction (p = 0.012, F = 7.050, Cohen's d = 0.89) was found for correct responses on the Response Inhibition task, but not for ADAS-Cog. Moreover, a significant time*group interaction for Quinolinic acid to Tryptophan ratios (p = 0.022, F = 5.769, Cohen's d = 0.84) in favor of the golf group was observed. An uncorrected negative correlation between attendance rate and delta Quinolinic acid to Kynurenic acid ratios in the golf group (p = 0.039, r=-0.443) was found as well. The findings indicate that learning golf is feasible and safe for elderly people with cognitive problems. Preliminary results suggest positive effects on attention and the KP. To explore the whole potential of golfing and its effect on cognitive decline, a larger cohort should be studied over a longer period with higher cardiovascular demands. The trial was retrospectively registered (2nd July 2018) at the German Clinical Trials Register ( DRKS00014921 ).
Sections du résumé
BACKGROUND
BACKGROUND
Subjective Memory Complaints (SMC) in elderly people due to preclinical Alzheimer's Disease may be associated with dysregulation of the Kynurenine Pathway (KP), with an increase in neurotoxic metabolites that affect cognition. Golf is a challenging sport with high demands on motor, sensory, and cognitive abilities, which might bear the potential to attenuate the pathological changes of preclinical AD. This trial investigated the feasibility of learning to play golf for elderly with cognitive problems and its effects on cognitive functions and the KP.
METHODS
METHODS
In a 22-week single-blinded randomized controlled trial, elderly people with SMC were allocated to the golf (n = 25, 180 min training/week) or control group (n = 21). Primary outcomes were feasibility (golf exam, adherence, adverse events) and general cognitive function (Alzheimer's Disease Assessment Scale). Secondary outcomes include specific cognitive functions (Response Inhibition, Corsi Block Tapping Test, Trail Making Test), KP metabolites and physical performance (6-Minute-Walk-Test). Baseline-adjusted Analysis-of-Covariance was conducted for each outcome.
RESULTS
RESULTS
42 participants were analyzed. All participants that underwent the golf exam after the intervention passed it (20/23). Attendance rate of the golf intervention was 75 %. No adverse events or drop-outs related to the intervention occurred. A significant time*group interaction (p = 0.012, F = 7.050, Cohen's d = 0.89) was found for correct responses on the Response Inhibition task, but not for ADAS-Cog. Moreover, a significant time*group interaction for Quinolinic acid to Tryptophan ratios (p = 0.022, F = 5.769, Cohen's d = 0.84) in favor of the golf group was observed. An uncorrected negative correlation between attendance rate and delta Quinolinic acid to Kynurenic acid ratios in the golf group (p = 0.039, r=-0.443) was found as well.
CONCLUSIONS
CONCLUSIONS
The findings indicate that learning golf is feasible and safe for elderly people with cognitive problems. Preliminary results suggest positive effects on attention and the KP. To explore the whole potential of golfing and its effect on cognitive decline, a larger cohort should be studied over a longer period with higher cardiovascular demands.
TRIAL REGISTRATION
BACKGROUND
The trial was retrospectively registered (2nd July 2018) at the German Clinical Trials Register ( DRKS00014921 ).
Identifiants
pubmed: 34001020
doi: 10.1186/s12883-021-02186-9
pii: 10.1186/s12883-021-02186-9
pmc: PMC8127313
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
200Références
BMC Psychiatry. 2011 Jul 01;11:108
pubmed: 21722382
Int J Environ Res Public Health. 2013 Aug 30;10(9):3967-86
pubmed: 23999546
J Clin Epidemiol. 1993 Feb;46(2):153-62
pubmed: 8437031
Clin Lab. 2010;56(9-10):441-8
pubmed: 21086789
Aging Ment Health. 2020 May;24(5):709-716
pubmed: 30588848
J Int Neuropsychol Soc. 2017 Sep;23(8):617-626
pubmed: 28693655
Alzheimers Dement. 2015 Nov;11(11):1385-92
pubmed: 25667997
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Alzheimers Dement. 2017 Mar;13(3):296-311
pubmed: 27825022
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
BMJ Open. 2018 Jul 19;8(7):e021610
pubmed: 30030318
Neurology. 2018 Apr 10;90(15):e1298-e1305
pubmed: 29540588
Front Psychiatry. 2015 Aug 20;6:116
pubmed: 26347662
J Epidemiol Community Health. 2018 Oct;72(10):944-950
pubmed: 29936419
JAMA. 2008 Sep 3;300(9):1027-37
pubmed: 18768414
Front Aging Neurosci. 2017 Mar 14;9:56
pubmed: 28352225
J Thorac Dis. 2016 Sep;8(9):E928-E931
pubmed: 27747028
Physiol Behav. 2018 Oct 1;194:583-587
pubmed: 30031753
Curr Top Behav Neurosci. 2017;31:117-138
pubmed: 27225497
Acta Oncol. 2019 May;58(5):579-587
pubmed: 30696326
Front Oncol. 2019 Sep 25;9:962
pubmed: 31612110
Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):345-52
pubmed: 23192697
Brain Behav Immun. 2019 Jan;75:155-162
pubmed: 30675874
Acta Psychiatr Scand. 2014 Dec;130(6):439-51
pubmed: 25219393
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
Prog Cardiovasc Dis. 2019 Mar - Apr;62(2):94-101
pubmed: 30802460
Br J Sports Med. 2017 Jan;51(1):12-19
pubmed: 27697939
Nat Rev Neurosci. 2000 Dec;1(3):191-8
pubmed: 11257907
Neuropharmacology. 2017 Jan;112(Pt B):237-247
pubmed: 27511838
Ageing Res Rev. 2017 Aug;37:117-134
pubmed: 28587957
J Clin Med. 2019 Jun 28;8(7):
pubmed: 31261796
Sci Rep. 2018 May 22;8(1):8008
pubmed: 29789640
Chest. 2003 Feb;123(2):387-98
pubmed: 12576356
Am J Psychiatry. 1984 Nov;141(11):1356-64
pubmed: 6496779
Front Hum Neurosci. 2011 Mar 17;5:26
pubmed: 21441997
Int J Tryptophan Res. 2009;2:1-19
pubmed: 22084578
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S151-9
pubmed: 26402082
BMJ Open. 2015 Sep 16;5(9):e007936
pubmed: 26377504
PLoS One. 2018 Jul 11;13(7):e0196636
pubmed: 29995884
Neurochem Int. 2007 Jan;50(2):308-13
pubmed: 17023091
Alzheimers Dement (Amst). 2015 Mar 1;1(1):33-40
pubmed: 25938132
BMC Public Health. 2010 Aug 04;10:456
pubmed: 20684754
PM R. 2014 Sep;6(9):825-7
pubmed: 24713179
PLoS One. 2009;4(3):e4785
pubmed: 19277116
Aging Ment Health. 2017 Mar;21(3):313-321
pubmed: 26329364
Cells. 2019 Jul 09;8(7):
pubmed: 31324021
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3017-22
pubmed: 21282661
Int J Geriatr Psychiatry. 2008 Nov;23(11):1191-202
pubmed: 18500688
PLoS One. 2013 Apr 09;8(4):e61483
pubmed: 23585901
J Alzheimers Dis. 2017;60(2):495-504
pubmed: 28869479
Science. 2017 Jul 28;357(6349):
pubmed: 28751584
Menopause. 2012 Jul;19(7):735-41
pubmed: 22415562
Exerc Immunol Rev. 2020;26:24-42
pubmed: 32139353
Front Neurosci. 2010 Dec 08;4:189
pubmed: 21151782
Front Aging Neurosci. 2019 Jan 25;11:7
pubmed: 30760996
Int Psychogeriatr. 2015 May;27(5):865-73
pubmed: 25567412
J Alzheimers Dis. 2017;59(3):1097-1111
pubmed: 28731451
J Alzheimers Dis. 2019;71(3):785-795
pubmed: 31424391